


# Accepted Manuscript

Surrogate Endpoints and Risk Adaptive Strategies In Previously Untreated Follicular Lymphoma

M.S. Narkhede, B.D. Cheson



PII: S2152-2650(18)30033-8

DOI: [10.1016/j.clml.2018.04.008](https://doi.org/10.1016/j.clml.2018.04.008)

Reference: CLML 1101

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 17 January 2018

Revised Date: 29 March 2018

Accepted Date: 27 April 2018

Please cite this article as: Narkhede MS, Cheson BD, Surrogate Endpoints and Risk Adaptive Strategies In Previously Untreated Follicular Lymphoma, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.04.008.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

SURROGATE ENDPOINTS AND RISK ADAPTIVE STRATEGIES IN FOLLICULAR LYMPHOMA

# SURROGATE ENDPOINTS AND RISK ADAPTIVE STRATEGIES IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

M.S.Narkhede, B.D.Cheson

## Author affiliations

Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC, USA

Corresponding Author

Dr. Bruce D Cheson

Lombardi Comprehensive Cancer Center,

Medstar Georgetown University Hospital,

3800 Reservoir Road Northwest

Lombardi Comprehensive Cancer Center Podium A

Washington, DC 20007, USA

**Phone:** (202) 444-2223

**Fax:** (202) 444-1229

**E-Mail** bdc4@georgetown.edu

## Abstract:

Follicular lymphoma is the second most common subtype of non-Hodgkin's lymphoma with an estimated 3.18 cases per 100,000 people. Despite the prolongation of survival with chemoimmunotherapy, variability in response to initial treatment and outcome still exists. Whereas prolonging overall survival is important, it is generally an unreasonable primary endpoint in the front-line setting. Long follow-up needed and the influence of subsequent therapies creates a potential bias. Thus, clinical trials require approximately 5 to 8 years from activation to completion and analysis of outcomes. This duration results in enormous cost and a delay in developing newer therapies. Thus, there is a need to identify markers or surrogate endpoints that can be used in clinical trials to expedite the development of new treatments. This review will

Download English Version:

<https://daneshyari.com/en/article/8615294>

Download Persian Version:

<https://daneshyari.com/article/8615294>

[Daneshyari.com](https://daneshyari.com)